Literature DB >> 11680546

Prevalence of hepatitis B markers in patients with hepatitis C infection in north-eastern Poland: risk factors and vaccine use.

S Chlabicz1, A Grzeszczuk.   

Abstract

We evaluated the prevalence of hepatitis B virus (HBV) markers and established HBV vaccination status among 111 patients with hepatitis C virus (HCV) infection. A history of HBV immunisation was recorded in 30 patients (27.0%) and only 17/30 (66.7%) had anti-HBs level > or =10 mIU/ml. All patients were HBsAg-negative and 22.2% of nonvaccinated subjects had evidence of HBV infection as determined by anti-HBc presence. Among patients with anti-HBc in 7/18 cases (38.9%) anti-HBc was the only marker of HBV infection (without anti-HBs). The prevalence of anti-HBc was significantly higher among patients who reported a history of acute hepatitis. In conclusion the prevalence of HBV markers in patients with HCV infection in north-eastern Poland is similar to the prevalence in general population, which suggests no increased risk for nosocomial HBV infection among those individuals. HCV infection seems to favour unusual serological pattern of HBV infection with anti-HBc as the only marker. HBV vaccine use is low among patients with HCV infection in north-eastern Poland.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680546     DOI: 10.1023/a:1017934410028

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  9 in total

1.  Hepatitis B epidemiology in Poland, Central and Eastern Europe and the newly independent states.

Authors:  W W Magdzik
Journal:  Vaccine       Date:  2000-02-18       Impact factor: 3.641

2.  [Occurrence of antigens and specific antibodies against hepatitis B virus infection in relation to other immunoserological indicators in alcohol-dependent persons].

Authors:  P Boroń; E Bobrowska; A Borzuchowska; A Kaczmarska; H Kamińska; D Prokopowicz; T Szpakowicz; Z Sidun
Journal:  Przegl Epidemiol       Date:  1987

3.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.

Authors:  I Cacciola; T Pollicino; G Squadrito; G Cerenzia; M E Orlando; G Raimondo
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

4.  High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan.

Authors:  H Marusawa; Y Osaki; T Kimura; K Ito; Y Yamashita; T Eguchi; M Kudo; Y Yamamoto; H Kojima; H Seno; F Moriyasu; T Chiba
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

5.  Response of patients with dual hepatitis B virus and C virus infection to interferon therapy.

Authors:  Y F Liaw; R N Chien; S M Lin; C T Yeh; S L Tsai; I S Sheen; C M Chu
Journal:  J Interferon Cytokine Res       Date:  1997-08       Impact factor: 2.607

6.  Characteristics of patients with dual infection by hepatitis B and C viruses.

Authors:  J P Zarski; B Bohn; A Bastie; J M Pawlotsky; M Baud; F Bost-Bezeaux; J Tran van Nhieu; J M Seigneurin; C Buffet; D Dhumeaux
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

7.  HCV infection in Poland.

Authors:  K Bielawski; M Wlasiuk; M Truskolawska; B Falkiewicz
Journal:  Arch Med Res       Date:  2000 Sep-Oct       Impact factor: 2.235

8.  Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells.

Authors:  C M Shih; S J Lo; T Miyamura; S Y Chen; Y H Lee
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus.

Authors:  W Jilg; E Sieger; R Zachoval; H Schätzl
Journal:  J Hepatol       Date:  1995-07       Impact factor: 25.083

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.